To test the sensitivity of waist circumference (central adiposity) as an index of disease risk in postmenopausal women.
Introduction
A high body mass index (BMI, kgam 2 ) is associated with increased mortality from all causes and from cardiovascular disease in middle-aged and older adults. 1, 2 Based on this association health professionals are currently using BMI as a means of categorizing a patient's relative risk of disease. However, it is becoming increasingly clear that body fat distribution is a more important determinant of disease risk than body mass. Individuals with a high proportion of abdominal fat have a greater risk of developing type 2 diabetes mellitus, 3, 4 coronary artery disease (CAD), 5 and cardiovascular disease (CVD)-related mortality. 6 Although the mechanism is unknown, it is postulated that central adiposity, speci®cally excess visceral adipose tissue, is associated with CAD and CVD-related mortality primarily through its impact on insulin resistance and dyslipidemia. 7, 8 As women progress through the menopause, changes in body fat distribution may contribute to an increase in disease risk. Abdominal adiposity increases markedly after the menopause, 9 as does the incidence of cardiovascular and metabolic diseases. 5, 10 The menopause-related increase in adiposity is countered by an accelerated loss of lean mass, 11 such that body weight does not change signi®cantly. 12 Thus, through these transitional years, BMI is likely to be an insuf®cient measure of relative risk of disease and mortality. Waist circumference appears to be the best simple anthropometric measure of abdominal fat and, importantly, visceral adipose tissue in younger women 13 and may potentially be a more sensitive measure of disease risk than BMI in postmenopausal women. Furthermore, a large waist circumference has been linked to an impairment in general health and quality of life in young and middle-aged women.
14 Therefore, we sought to determine in a large cohort of healthy postmenopausal women whether waist circumference: (1) is related to three important predictors of disease risk (hyperinsulinemia, triglycerides and high-density lipoprotein (HDL)-cholesterol); (2) is a more robust index of disease risk than BMI; and (3) maintains a linear (dose-dependent) relation with disease risk in normal-weight individuals.
Methods

Subjects
Body composition and CVD risk factors were measured in 323 healthy postmenopausal (66 AE 5 y) women recruited from the greater St Louis metropolitan area. All women were at least 2 y past menopause (18 AE 7 y), not using any type of hormone replacement, non-smokers and free of overt heart disease, as assessed by resting and exercise 12-lead ECG, and diabetes mellitus, as assessed by an oral glucose tolerance test (OGTT). 15 All of the participants provided written informed consent to participate in the study, which was approved by the Washington University Institutional Review Board.
Body composition
Hydrodensitometric and anthropometric measures of body composition were performed as previously described. 16 Brie¯y, body density was measured using underwater weighing and body fat percentage was estimated from body density using the equation of Brozek et al. 17 Waist circumference was measured in triplicate at the mid-point between the distal border of the ribs and the top of the iliac crest. Weight and height were measured using a physician's balance scale and a stadiometer respectively. All measurements were made by trained research technicians.
Blood lipids and lipoproteins
Measurement of serum lipid and lipoprotein concentrations was performed in the Core Laboratory for Clinical Studies at Washington University. Cholesterol and glycerol-blanked triglycerides were measured by automated enzymatic commercial kits (MilesaTechnicon, Tarrytown, NY). HDL-cholesterol was measured in plasma after precipitation of apolipoprotein B-containing lipoproteins by dextran sulfate (50 000 MW) and magnesium. 18 Low-density lipoprotein (LDL)-cholesterol was calculated using the Friedewald equation. 19 These methods are continuously standardized by the Lipid Standardization Program of the Centers for Disease Control and Prevention.
Glucose tolerance test
Glucose tolerance was determined using a 75 g OGTT, performed in the morning after an overnight fast. Diet was monitored for 3 days prior to the OGTT to ensure an intake of b 150 g of carbohydrate per day. Blood samples (3.0 mL) were obtained for the determination of glucose (glucose oxidase method; Beckman glucose analyzer) and insulin 20 immediately before and 30, 60, 90, 120 and 180 min after the glucose challenge. The total areas under the glucose and insulin curves were calculated using the trapezoidal rule.
Statistics
The primary outcome variables (insulin area, triglyceride and HDL-cholesterol) for analysis in this study were chosen a priori. Data were analyzed using two approaches to determine whether waist circumference or BMI was a more important predictor of the outcome measures of interest. The ®rst used partial correlation coef®cients between: (1) BMI and the outcome measures after adjusting for waist size, and (2) waist size and the outcome measures after adjusting for BMI. The relative value of these coef®cients and of the associated signi®cance levels provided an assessment of whether one predictor was more important than the other. The second approach began by dividing waist size into tertiles, thereby producing a middle tertile with a narrow range that, for all practical purposes, produced a sample of women with similar and normal waist size. Within this tertile of women with normal waist size, the signi®cance of BMI as a predictor of the outcome measures was assessed using regression analysis. Similarly, using the middle tertile of essentially similar and normal BMI values, regression analysis was used to evaluate the signi®cance of waist size. The contrast between (1) the signi®cance of BMI when waist size was held constant and (2) the signi®cance of waist size when BMI was held constant provided a second assessment of the relative importance of the two predictors. Because the variables were skewed, all analyses involving insulin area and triglycerides were performed following a logarithmic transformation. All data were analyzed using SAS and results are presented as mean AE s.e. unless stated otherwise.
Results
Body composition, lipid and glucose tolerance tests were performed in 323 postmenopausal women. Subject characteristics are provided in Table 1 . Both BMI and waist circumference were strongly and signi®cantly (P`0.01) correlated with percentage body fat (r 0.91 and 0.85, respectively).
To assess the relative importance of waist circumference and BMI as predictors of three prospectively chosen variables (OGTT insulin area, triglycerides and HDL-cholesterol), two related types of analyses were performed. First, Table 2 summarizes the results of partial correlation analyses Waist circumference after menopause RE Van Pelt et al between waist (after adjusting for BMI) or BMI (after adjusting for waist) and the three dependent variables of interest. After adjusting for BMI, a strong relation existed between waist circumference and insulin area, HDL-cholesterol and triglycerides (P 0.0l). Conversely, after adjusting for waist circumference, no signi®cant relation was apparent between BMI and the dependent variables of interest.
For the second part of the analyses, waist circumference and BMI data were grouped by tertiles ( Table 3) . As anticipated, a strong dose-dependent relation existed between waist circumference or BMI and the outcome measures (P`0.001 in all cases) when these variables were considered separately. However the increased predictive value of waist circumference, as compared to BMI, is apparent in the ®gure. Women who fell into the middle waist and BMI tertiles were further divided into sub-tertiles to test the hypothesis that waist circumference is a more sensitive predictor of disease risk than BMI within a narrow range of body size. Figure 1A contains data for the 110 subjects in the middle tertile for BMI (range of 24.5±27.9 kgam 2 ) and indicates a consistent and marked increase in insulin area with increasing waist size, (7100 AE 687 vs 8950 AE 512 vs 11 709 AE 1031 mUamL min, P`0.001). Figure 1B , on the other hand, contains the data for the 109 subjects in the middle waist tertile (range of 78.8±88.0 cm). In contrast with Figure 1A , insulin areas were not different across groups and actually declined slightly, from 9112 AE 714 mUamL min in the lowest BMI group to 8950 AE 400 and 8036 AE 676 mUamL min in the middle and highest BMI, respectively. Similar relations were observed between waist or BMI group and serum triglycerides. Among the subjects in the middle tertile for BMI, serum triglycerides ranged from 128 AE 21 mgadL in the lowest to 142 AE 13 and 149 AE 16 mgadL in the middle and highest waist group, respectively ( Figure 1C ). In contrast, there was no association between BMI and triglycerides for women in the middle waist tertile ( Figure 1D ). Serum HDL-cholesterol levels were not in¯uenced by either waist size or BMI within the middle tertile groups (Figure 1E and 1F) .
Discussion
We investigated the relation between waist size and markers of insulin resistance and dyslipidemia in a large cohort of postmenopausal women. The results of this study indicate that: (1) waist size is more strongly associated with disease risk than is BMI in healthy, postmenopausal women; (2) this association is linear, such that serum insulin area and triglycerides are positively related, and HDL-cholesterol concentration is negatively related with waist size; and (3) the strong positive association between waist size and both insulin area and triglycerides continues to hold when the analyses are restricted to normal weight women within a narrow range of BMI (24 ± 28 kgam 2 ). That is, increased waist size indicates increased risk, when BMI is held constant and normal. However, in marked contrast, when analyses are restricted to women within a narrow range of waist size, BMI is not an important predictor of risk.
Body mass tends to increase with age in adults and is associated with increased risk of disease and mortality. 1, 2 However, weight gain is not dramatic among women at the time of menopause. This was previously demonstrated in a longitudinal study by Wing et al in which the body weight of 485 middle-aged women was followed over a 3 y period. 12 After 3 y, weight gain was not signi®cantly different in women who remained premenopausal compared with those who had undergone natural menopause (2.07 vs 1.35 kg). On the other hand, changes in body composition become more readily apparent as women progress through the menopause. A 6 y study by Poehlman et al found that Waist circumference after menopause RE Van Pelt et al premenopausal women who became postmenopausal during the period of the study had a 3.0 AE 1.1 kg decrease in fat-free mass and a 2.5 AE 2.0 kg increase in fat mass. 11 Age-matched women who remained premenopausal through the period of the study had non-signi®cant changes in fat-free mass and fat mass (70.5 AE 0.5 and 1.0 AE 1.5 kg, respectively). Similarly, ) among individuals, differences in waist circumference predict insulin area and triglycerides. However, when waist is constant (78.5 ± 88.0 cm) among individuals, differences in BMI do not predict insulin area and triglycerides.
Waist circumference after menopause RE Van Pelt et al a study by Bjorkelund and colleagues found that women going through the menopause had greater increases in waist circumferences and waist±hip ratios than women who remained pre-menopausal. Moreover, both groups had identical changes in BMI within this transitional period. 21 Clearly increases in fat mass, rather than body mass per se, cause deleterious effects on the metabolic pro®le of aging women. Fat mass accumulation further adds to the risk of disease as abdominal obesity is associated with greater incidence of type 2 diabetes mellitus, disturbances in lipid metabolism 7, 8 and increased mortality 6 than is total degree of adiposity. The body fat distribution of women changes signi®cantly at the time of menopause, with a shift from preferential storage in glutealafemoral regions to abdominal depots. Studies suggest that it is declining sex hormones, rather than aging, that trigger the menopause-related increase in abdominal adiposity 22, 23 and the accompanying unfavorable changes in the metabolic pro®le. 24, 25 However, prospective studies are needed to determine whether the increase in abdominal adiposity with the menopause involves a preferential deposition of fat in visceral regions. It is likely that greater central fat accumulation is due to increases in visceral adipose tissue and that this contributes to the increase in risk for cardiovascular and metabolic abnormalities that occurs after the menopause.
It is important to emphasize that an increase in abdominal fat may not be an inevitable consequence of aging or menopause. Lifestyle factors, such as regular physical activity, may prevent or at least attenuate gains in abdominal adiposity. This is supported by the observation that women who are physically active demonstrate less of an age-related increase in trunk fat mass compared with their sedentary peers. 26 Furthermore, menopause-related increases in abdominal fat are potentially reversible. This is supported by evidence that postmenopausal women can improve their pattern of fat distribution with regular exercise. 27 There are also data to suggest that certain hormone replacement regimens may attenuate accumulation of abdominal fat after menopause. 23, 25, 28 Advances in technology have allowed investigators to distinguish between centrally located visceral and subcutaneous adipose tissue using computed tomography (CT) or magnetic resonance imaging (MRI). However, measurement of visceral adipose tissue by CT or MRI is impractical for health screening. Both BMI and waist circumference are good`®eld measures' of adiposity that are easily measured in clinical settings. Results of the current study suggest that waist circumference is a more sensitive indicator of disease risk than BMI in postmenopausal women. It might be argued that waist circumference is simply a better marker of total adiposity than BMI and that this accounts for its sensitivity as a predictor of disease risk. However, in our postmenopausal women both waist circumference and BMI were equally strong predictors of fat mass, suggesting that the difference between the two measures lies in the ability of the waist circumference to capture abdominal adiposity. This possibility is supported by the fact that waist circumference has been validated against CT as the best simple estimate of visceral adipose tissue. 13 In the current study, risk of disease increased as waist size increased from lowest (`78.5 cm) to middle (78.5 ± 88.0 cm) to highest (b 88.0 cm) in postmenopausal women. These waist tertiles are consistent with levels previously reported in a study by Lean et al 14 in which larger waist circumferences were associated with impairments in health and quality of life indexes in young and middle-aged men and women. In that study, women who had waist circumferences in excess of 88.0 cm had greater incidence of type 2 diabetes as well as increased dif®culties with lower back pain and physical functioning than women with lower waist circumferences. Although it may be clear that women with waist girths greater than 88.0 cm are at a much higher risk of disease and functional impairment, the same could be said for women whose BMI is greater than 28 kgam 2 . The present study emphasizes the impact of waist size on disease risk independent of BMI. Women in this study who did not differ with respect to BMI, but differed in waist size demonstrated signi®cant differences in metabolic pro®le. On the other hand, the disease risk pro®les of women with similar waist size, but different BMI were not distinguishable. It is important that clinicians understand the negative impact that increases in waist size can have on disease risk independent of changes in body weight or BMI.
In summary, because waist size is (1) associated with metabolic markers of disease risk in postmenopausal women and (2) easy to measure, we recommend that healthcare professionals monitor changes in waist circumference in postmenopausal women in conjunction with body weight and standard metabolic screening. This practice should not be limited to obese women because even small increases in abdominal adiposity in normal-weight women may contribute to unfavorable changes in the metabolic pro®le.
